November 16, 2015 - ZOLL LifeVest Wearable Defibrillator to Be Showcased at the 2015 Asia Pacific Heart Rhythm Society Scientific Sessions

CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
[email protected]

 

 

ZOLL LIFEVEST WEARABLE DEFIBRILLATOR TO BE SHOWCASED AT THE 2015 ASIA PACIFIC HEART RHYTHM SOCIETY SCIENTIFIC SESSIONS

November 16, 2015—CHELMSFORD, MASS.—ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that it will display the LifeVest® Wearable Defibrillator in Booth 34 at the 2015 Asia Pacific Heart Rhythm Society Scientific Sessions, 19–22 November in Melbourne, Australia.

The LifeVest will be discussed during the following scientific sessions:

  • A satellite symposium entitled “1 in 14 Patients Require Arrhythmia Intervention: Protecting Patients with the Wearable Cardioverter Defibrillator” will be chaired by Andrew Epstein, MD, University of Pennsylvania, and presented by Shingo Sasaki, MD, Hirosaki University, Japan, Saturday, 21 November, 12:00-13:00, Room 211.
  • Andrew Epstein, MD, University of Pennsylvania, will present “Wearable Cardioverter Defibrillator: State of the Art,” Saturday, 21 November, 16:00-17:40, Room 103.

The LifeVest protects patients at risk for sudden cardiac death (SCD). It is used for a wide range of patient conditions or situations, including following a myocardial infarction, before or after coronary revascularization, and for those with cardiomyopathy or congestive heart failure that places them at particular risk. The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden death.

In the WEARIT-II prospective registry of 2,000 patients prescribed the LifeVest, the sustained VT/VF event rate was high with 22 events per 100 patient-years—2.1% of patients had a VT/VF event.1 One in 14 patients experienced a clinically meaningful arrhythmia requiring intervention while wearing the LifeVest.1 The LifeVest Network online patient data management system provides customizable tools for physicians and clinicians to access these captured arrhythmias, like atrial fibrillation or non-sustained ventricular tachyarrhythmias, and determine the appropriate intervention.

The LifeVest is lightweight and easy to wear, allowing patients to return to their common activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group Company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

1Kutyifa V, et al. Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients: Data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation. 2015; published online before print August 27, 2015.

Copyright © 2015 ZOLL Medical Corporation. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.